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Latency-associated nuclear antigen 1 (LANA1) of Kaposi’s sarcoma-associated herpesvirus (KSHV) is
implicated in the maintenance of the viral genome during latent infection. LANA1 colocalizes with KSHV
episomes on the host chromosome and mediates their maintenance by attaching these viral structures to host
chromosomes. Data from long-term selection of drug resistance in cells conferred by plasmids containing the
terminal repeat (TR) sequence of KSHV revealed that KSHV TRs and LANA1 act as cis and trans elements of
viral latent replication, respectively. In this study, we further characterized the cis- and trans-acting elements
of KSHV latent replication by using a transient replication assay with a methylation-sensitive restriction
enzyme, DpnI. Transient reporter and replication assays disclosed that the orientation and basal transcrip-
tional activity of TR constructs did not significantly affect the efficiency of replication. However, at least two TR
units were necessary for efficient replication. The N-terminal 90 amino acids comprising the chromosome-
binding domain of LANA1 were required for the mediation of LANA1 C-terminal DNA-binding and dimer-
ization domains to support the transient replication of KSHV TRs. LANA1 interacted with components of the
origin recognition complexes (ORCs), similar to Epstein-Barr virus nuclear antigen 1. Our data suggest that
LANA1 recruits ORCs to KSHV TRs for latent replication of the viral genome.
Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV)/hu-
man herpesvirus 8 is a member of the gammaherpesvirus
group, along with the closely related herpesvirus saimiri and
Epstein-Barr virus (EBV). KSHV is implicated in KS and
several lymphoproliferative diseases, including primary effu-
sion lymphoma or body cavity-based lymphoma and some
cases of multicentric Castleman’s disease (9, 10, 36). KSHV
DNA is found in the endothelial and spindle cells of KS le-
sions, as well as lymphocytes and lymphoid tissues, and estab-
lishes a predominantly latent state of infection. During latent
infection, only a small subset of viral genes is expressed (47),
and the circularized viral genome is maintained as a multicopy
episome (8, 13). Following chemical treatment or overexpres-
sion of KSHV open reading frame 50, the lytic cycle is induced,
resulting in virus particle production (30, 31, 35, 37, 44, 51).
Latency-associated nuclear antigen 1 (LANA1), originally
identified by use of an immunofluorescence assay with the sera
of KS patients (16, 24), is one of the latent genes encoded by
open reading frame 73 of the KSHV genome (40, 46). This
222- to 234-kDa nuclear protein, composed of 1,162 amino
acids, associates with the mitotic chromosome (5, 12, 38) and
binds to sites within the terminal repeat (TR) sequence of the
KSHV genome encompassing the putative origin of plasmid
replication (oriP) (6, 17), thereby allowing the stable mainte-
nance of plasmids containing this region (5, 6). Therefore, it
has been suggested that LANA1 plays an important role in the
maintenance of the KSHV genome during host cell mitosis by
tethering the viral episome to host chromosomes. These char-
acteristics imply that KSHV LANA1 is a functional analog of
EBV nuclear antigen 1 (EBNA-1) in the latent replication of
the viral genome. Additionally, LANA1 acts as a transcrip-
tional repressor when attached to promoters via the heterolo-
gous DNA-binding domain (DBD) (27, 49). The protein is
involved in the regulation of several viral and cellular promot-
ers, including the cyclin E promoter (CCNE1p) (39), the te-
lomerase reverse transcriptase promoter (hTERTp) (26), two
EBV latent promoters (Cp and LMP1p) (20, 27), long TRs of
human immunodeficiency virus type 1 (23, 45), the interleu-
kin-6 promoter (4), KSHV TRs (17), and its own promoter
(45). LANA1 also interacts directly with several cellular and
viral factors and regulates their transcriptional activities (15,
28, 29, 39).
The maintenance of the viral genome in host cells during
latent infection involves two distinct steps, specifically, repli-
cation of the viral genome by cellular machinery during the S
phase and the equal segregation or partition of the replicated
viral genome to daughter cells after mitosis of the host cell.
Previous studies on the latent replication of KSHV were based
on the long-term selection in cells of drug resistance conferred
by putative oriP-containing plasmids (5, 6). However, this assay
does not discriminate between the events of replication and
equal segregation and detects only the result of their cooper-
ation. In this study, we describe for the first time a transient
DNA replication assay for KSHV that uses a methylation-
sensitive enzyme, DpnI, which is unable to digest plasmids
replicated in eukaryotic cells. We investigate the roles of viral
trans- and cis-acting elements during latent infection in the
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replication and transcription of KSHV TRs, which encompass
the putative oriP.
MATERIALS AND METHODS
Plasmids. The pcDNA3 LANA1 and pFLAG-CMV2 LANA1 vectors and
deletion mutants of LANA1 were constructed as described previously (28, 29). A
BglII/EcoRI fragment of pM or pVP16 (Clontech, Palo Alto, Calif.) was inserted
into BamHI/EcoRI sites of pcDNA3 (Invitrogen, Carlsbad, Calif.) or its deriv-
atives to express the GAL4 DBD- or VP16 activation domain (AD)-fused pro-
tein driven by a cytomegalovirus (CMV) promoter, respectively. cDNA corre-
sponding to amino acids 1 to 90 of EBNA-1 was amplified with appropriate
primers from pCEP4 (Invitrogen) and inserted into the EcoRI site of pFLAG
LANA1 C to express an EBNA-1–LANA1 C hybrid protein.
The EcoRI/XhoI fragment of cosmid Z6 spanning from KSHV left-end TRs to
nucleotide 3235 of the KSHV long unique region (LUR) was cloned between the
corresponding restriction sites of pBluescript II KS() (Stratagene, San Diego,
Calif.) and designated pTR-3K. Partial NotI digestion of pTR-3K was performed
to construct vectors p4TR-3K, p2TR-3K, p1TR-3K, and p0TR-3K (designated
according to the number of TRs). The SacI/PstI fragments of these constructs
were inserted into the corresponding sites of pBluescript II KS() to remove
most of the KSHV LUR and designated pBS-4TR, pBS-2TR, pBS-1TR, and
pBS-0TR, respectively. Digested fragments (SacI/HindIII) of these constructs
were cloned into the corresponding sites of pGL2-basic (Promega, Madison,
Wis.) to generate p4TR-luc, p2TR-luc, p1TR-luc, and p0TR-luc, respectively.
From these plasmids, SacI/XhoI fragments were cloned into pGL3-promoter
(Promega) to generate p4TRSV-luc, p2TRSV-luc, p1TRSV-luc, and p0TRSV-
luc, respectively. One or two units of TRs were generated by partial NotI diges-
tion of p4TR-luc and inserted into the corresponding restriction site of pBlue-
script II KS(-). The orientation of the TR sequence was confirmed by restriction
enzyme mapping, followed by insertion into pGL2-basic to generate plasmids
p2xTR-luc, p2RxTR-luc, p1xTR-luc, and p1RxTR-luc, respectively. See Fig. 2A
for a schematic representation of various TR constructs.
The pGEX-hORC1, pGEX-hORC2, pGEX-hORC4, and pGEX-hORC5 con-
structs were generous gifts from H. Ariga (Hokkaido University, Hokkaido,
Japan). cDNA fragments from pGEX-hORC1 and pGEX-hORC2 were inserted
into BamHI/NotI sites of pcDNA3. N- or C-terminal deletion mutants of pGEX-
hORC1 and pGEX-hORC2 fused to glutathione S-transferase (GST) were gen-
erated by PCR with appropriate primers, followed by cloning into pGEX4T-1
(Amersham Pharmacia Biotech, Uppsala, Sweden).
Cell culture, transfection, and reporter assay. 293T cells were maintained and
transfected as described previously (28). BJAB cells, KSHV- and EBV-negative
B-cell lymphoma lines derived from EBV-negative Burkitt lymphoma biopsy
samples, were maintained in RPMI 1640 medium supplemented with 10% fetal
bovine serum and transfected by electroporation (31). A constant amount of
total DNA for transfection was maintained by using an appropriate blank vector.
The transient reporter assay was performed as described in an earlier study (28).
EMSA. An electrophoretic mobility shift assay (EMSA) was performed as
described previously, with minor modifications (6). Synthetic oligonucleotides
TR-13 (5-TCCCGCCCGGGCATGGGGCC-3) and TR-12 (5-CGGGCATG
GGGCCGCGCGCCGCC-3) with 5-GATC overhangs were labeled with
[-32P]ATP by using T4 polynucleotide kinase and annealed to complementary
strands. LANA1 and derivatives were synthesized by using the TNT T7 coupled
transcription-translation reticulocyte lysate system according to the manufactur-
er’s instructions (Promega). Labeled probe (approximately 200 fmol per reac-
tion) was incubated with 3 l of in vitro-translated LANA1 or its derivatives in
binding buffer 1 [20 mM Tris (pH 7.5), 10% glycerol, 50 mM KCl, 0.1 mM
dithiothreitol, 10 mM MgCl2, 1 mM EDTA, 1 g of poly(dI-dC)] at room
temperature for 30 min. Unlabeled specific or nonspecific competitors were
included in the reaction mixtures (at a 12.5- to 50-fold excess) when needed.
Reactions were terminated by loading onto a 3.5% native polyacrylamide gel in
Tris-borate-EDTA running buffer. The gel was dried and subjected to autora-
diography.
Transient replication assay. 293T cells in 100-mm dishes were cotransfected
with 2 g of oriP-containing plasmid, 2 g of pGL2-basic as an internal control,
and 8 g of trans-acting element expression plasmid. At 36 h posttransfection,
293T cells were trypsinized, collected by centrifugation, and serially split to make
equal amounts of cells (5 106 cells per sample) at harvesting time. BJAB cells
were cotransfected with 7.5 g of oriP-containing plasmid, 7.5 g of pGL2-basic
as an internal control, and 15 g of trans-acting element expression plasmid.
Following electroporation, BJAB cells were serially split to make equal amounts
of cells (107 cells per sample) at harvesting time. Cells were washed twice with
phosphate-buffered saline, and low-molecular-weight DNA was extracted by the
Hirt lysis method (21). Supernatants were successively extracted with phenol-
chloroform-isoamyl alcohol and chloroform. Ethanol-precipitated DNA was dis-
solved in 50 l of distilled water containing RNase. Thirty percent of Hirt-
extracted DNA from5 106 293T cells and107 BJAB cells was digested with
DpnI and Alw44I to remove unreplicated DNA and linearize pGL2-basic deriv-
atives, respectively. The completion of DpnI digestion was routinely checked by
monitoring the complete digestion of the unreplicated internal control, pGL2-
basic. Digested DNA was separated by 0.8% agarose gel electrophoresis and
analyzed by Southern blot hybridization. Probes specific for the luciferase gene
of pGL2-basic were synthesized with an NEBlot Phototope kit and detected with
a Phototope-Star detection kit according to the manufacturer’s instructions (New
England Biolabs, Beverly, Mass.).
In vitro binding assay. Escherichia coli expressing GST fusion proteins was
harvested and stored at 70°C until use. Cell pellets were resuspended in
binding buffer 2 (20 mM Tris [pH 7.5], 50 mM NaCl, 2 mM MgCl2, 1 mM
dithiothreitol, 0.5% Nonidet P-40) with brief sonication. After removal of cell
debris, the supernatants were incubated with glutathione-Sepharose 4B beads
(Amersham Pharmacia Biotech) at 4°C for 1 h. The resin was washed twice, and
in vitro-translated 35S-labeled protein was added. After a further 3 h of incuba-
tion at 4°C, the resin was washed four times with binding buffer 2, and bound
proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and autoradiography. When needed, 1 mM ATP and 50 pmol of double-
stranded oligonucleotide were included in the binding reaction mixtures. Puri-
fication of His-tagged LANA1 and LANA1 N by using a recombinant
baculovirus expression system and pull-down assays with Ni-nitrilotriacetic
acid–agarose were performed as described previously (29).
RESULTS
Integration of the C terminus of KSHV LANA1 is important
for binding to the TR region of the KSHV genome. Previous
reports showed that LANA1 binds the imperfect 20-nucleotide
palindromic sequence within the TR region of the KSHV ge-
nome (TR-13) via its C-terminal domain (6, 17). The location
of the LANA1-binding sequence within the TR region is de-
picted in Fig. 1A. As described previously, in vitro-translated
LANA1 interacted with TR-13 (Fig. 1B, lane 2). The addition
of excess, unlabeled TR-13 (lanes 3 and 4) but not unlabeled
TR-12 (lanes 5 and 6), spanning another portion of the TR
region, resulted in competition for binding to LANA1, further
confirming the specificity of this interaction. Similar results
were obtained with nuclear extracts from 293T cells trans-
fected with a FLAG-tagged LANA1 expression vector (data
not shown).
For fine mapping of the LANA1 DBD, a series of deletion
mutants were constructed and tested for TR-13-binding ability
in an EMSA. A schematic diagram of the LANA1 deletion
mutants used in EMSA analyses is depicted in Fig. 1C. The
expression of these mutant proteins was confirmed by their
sizes upon in vitro translation in the presence of [35S]methi-
onine (data not shown). As shown in Fig. 1D, the C terminus
of LANA1 was necessary and sufficient for binding to TR-13,
although the bands shifted by LANA1 C were weak and not
discrete. However, the GAL4 DBD fused to the C terminus of
LANA1 (but not the GAL4 DBD alone) clearly bound to
TR-13, suggesting that the C terminus of LANA1 acts inde-
pendently as a DNA-binding module, similar to the GAL4
DBD. In addition, a small C-terminal truncation or internal
deletion within the C terminus of LANA1 completely abol-
ished TR-13 binding ability (Fig. 1E), indicating that the over-
all structure of the C terminus of LANA1 is required for DNA
binding.
Binding of LANA1 via the C terminus results in the tran-
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scriptional repression of TRs. From cosmid Z6 spanning the
region between the left-end TRs and the 33-kb LUR of the
KSHV genome, we subcloned a series of KSHV TR variants
into pGL2-basic (Fig. 2A) and examined their transcriptional
promoter activities in the absence or presence of LANA1. TR
sequences including the 127-bp left end of the LUR of KSHV
led to more than 20-fold transcriptional activation of pGL2-
basic, which was repressed by LANA1 (Fig. 2B). We also
subcloned KSHV TR variants into pGL3-promoter containing
the simian virus 40 (SV40) early promoter and examined their
transcriptional enhancer activities in the absence or presence
of LANA1. As shown in Fig. 2C, TR variants also induced the
transcriptional activation of pGL3-promoter containing the
SV40 early promoter. Interestingly, their transcriptional en-
hancer activities were increased in proportion to the number of
TR units and repressed by LANA1, consistent with earlier data
(17). However, reporter plasmids containing only TRs without
the left end of the LUR, such as p2xTR-luc, p2RxTR-luc,
p1xTR-luc, and p1RxTR-luc, did not show any promoter ac-
tivities in a similar transient reporter assay, although transcrip-
tional enhancer activities were seen with pGL3-promoter (data
not shown).
Next, we determined the specific domain of LANA1 respon-
sible for the transcriptional repression of KSHV TRs by using
a series of LANA1 deletion mutants in a transient reporter
assay. The results confirmed earlier data showing that the C
terminus of LANA1 alone was sufficient for the transcriptional
repression of KSHV TRs (17). Moreover, small deletions
within this region abolished activity (Fig. 2D), suggesting that
direct binding via the C terminus of LANA1 induced the tran-
scriptional repression of KSHV TRs. Since the C terminus of
LANA1 alone was sufficient for the DNA-binding module in
the EMSA and the transcriptional repression of TRs in a
transient reporter assay, we assumed that a transcriptional
activator tethered to TRs via the C terminus of LANA1 would
result in the transcriptional activation of TRs, although the
LANA1 C terminus itself repressed transcription from the
TRs. As shown in Fig. 2E, the herpes simplex virus VP16 AD
fused to LANA1 C efficiently activated the transcription of
KSHV TRs. This activation was not due to the complicated
FIG. 1. EMSAs of in vitro-translated LANA1 and derivatives. (A) Locations of LANA1-binding sequence, TR-13, and adjacent TR-12 within
the TR region of the KSHV genome. (B) Control reticulocyte lysate (IVT) (lane 1) or in vitro-translated LANA1 (IVT LANA1) (lanes 2 to 6)
was incubated with a radiolabeled TR-13 probe in an EMSA. Unlabeled competitors, such as TR-13 (lanes 3 and 4) or TR-12 (lanes 5 and 6), were
included at a 12.5- to 50-fold molar excess in the binding reaction mixture. (C) Schematic diagram of LANA1 deletion mutants used in EMSAs.
DED, aspartate/glutamate-rich repeat region. (D) In vitro-translated LANA1 deletion mutants containing the C terminus of LANA1 were used
in EMSAs. (E) In vitro-translated LANA1 deletion mutants containing small truncations or internal deletions within the LANA1 C terminus were
used in EMSAs. Nonspecific bands are marked by asterisks.
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transcriptional response of TRs to VP16 AD, since VP16 AD
activated the transcription of p4TR-luc only when fused to
LANA1 C (Fig. 2E) and VP16 AD fused to LANA1 C did not
activate the transcription of pGL2-basic, a backbone reporter
of p4TR-luc (data not shown). Taken together, these results
further validate the theory that the C terminus of LANA1 acts
independently as a DNA-binding module.
KSHV TRs replicate only in the presence of LANA1 in a
transient DNA replication assay. For the transient DNA rep-
lication assay, TR variants used in the transient reporter assay
along with pGL2-basic as an internal control were cotrans-
fected with a blank or an LANA1 expression vector into 293T
or BJAB cells. At 36 h posttransfection, cells were serially
split to make equal amounts of cells harvested at various times.
The levels of expression of LANA1 and the numbers of trans-
fected 293T cells were monitored by Western blotting with
rabbit anti-LANA1 polyclonal antiserum and anti--actin
monoclonal antibody, respectively (Fig. 3A). As shown in Fig.
3B, DpnI-resistant replicated plasmids containing TR units
(but not pGL2-basic) were detectable only in the presence of
LANA1 at 72 h posttransfection. Similar results were obtained
when BJAB cells were used instead of 293T cells (Fig. 3C).
The EMSA and the transient reporter assay revealed that
LANA1 exerts transcriptional repressor activity on TRs by
direct binding. LANA1 also acts as a transcriptional repressor
when attached to the promoter via the heterologous DBD (27,
49) Therefore, we examined whether this protein could facili-
tate the replication of plasmid DNA when artificially tethered
to plasmid DNA via the GAL4 DBD. For this purpose, a
pFR-luc reporter plasmid containing five tandem GAL4-bind-
ing sites was cotransfected with a GAL4 DBD, a GAL4 DBD
fused to LANA1, or a LANA1 expression vector into 293T
cells, and a transient reporter assay was performed like that
described above. As shown in Fig. 3D, the pFR-luc reporter
plasmid was not replicated in the presence of either LANA1
alone or LANA1 fused to the GAL4 DBD. However, LANA1
fused to the GAL4 DBD but not LANA1 alone resulted in the
transcriptional repression of the pFR-luc reporter plasmid in
the transient reporter assay (data not shown), consistent with
previous reports (27, 49). These results reveal that the artificial
access of LANA1 in the vicinity of DNA is not sufficient for
supporting the initiation of DNA replication and that only
specific interactions between the viral trans- and cis-acting el-
ements of KSHV latent replication result in KSHV oriP activ-
ity.
A minimum of two LANA1-binding sites (LBSs) in TRs are
required for efficient replication. To examine the role of cis-
acting elements in KSHV oriP activity, the various TR con-
structs used in the transient reporter assay (Fig. 2A) were used
in a transient replication assay. As shown in Fig. 4A, TR
constructs, such as p4TR-luc, p2TR-luc, and p1TR-luc, which
contain more than two LBSs were efficiently replicated, while
p0TR-luc, with one LBS, was only weakly replicated. Similar
results were obtained when TR constructs containing only the
TR region without the left end of the KSHV LUR and dis-
playing no promoter activity were used in the replication assay.
TR orientation had no effect on the efficiency of replication
(Fig. 4B). These results suggest that basal transcription and
replication activities at KSHV oriP are uncoupled and that at
least two LBSs are required for efficient KSHV oriP activity.
Both N and C termini of LANA1 are required for KSHV oriP
activity. The EMSA and the transient reporter assay revealed
that the C-terminal domain of LANA1 is necessary and suffi-
cient for binding to the TR region, thereby resulting in the
transcriptional repression of KSHV TRs. To determine
whether the C terminus of LANA1 alone is sufficient to induce
KSHV oriP activity, various LANA1 deletion mutants were
used in a transient DNA replication assay. As expected,
LANA1 	C50, containing a small deletion at the LANA1 C
terminus, was unable to support KSHV oriP activity, indicating
that the direct binding of LANA1 to TRs is necessary for this
process (Fig. 5A). However, none of the N-terminal deletion
mutants of LANA1 which bound KSHV TRs and repressed its
transcription was also able to facilitate the replication of plas-
FIG. 1—Continued.
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mids containing KSHV TRs. A transient DNA replication as-
say with FLAG-tagged internal deletion mutants of LANA1
revealed that both the N and the C termini of LANA1 are
required for the efficient replication of the TR region (Fig.
5B). It is unlikely that the inability of LANA1 mutants to
support DNA replication was due to reduced expression levels
in transfected cells, since titration of increasing amounts of a
LANA1 expression vector and Western blotting data showed
that the transient DNA replication assay was performed under
conditions in which trans-acting element concentrations were
largely in excess (data not shown). Various sizes of faint DpnI-
resistant bands in Fig. 5A and darker ones in Fig. 5B were
pcDNA3 and pFLAG-CMV2 derivatives, respectively, because
they unexpectedly cross-reacted with the probe that we used.
They contained the SV40 origin of replication and replicated in
293T cells expressing SV40 large T antigen. Therefore, they
exhibited various sizes of DpnI-resistant bands according to
LANA1 deletion mutants.
A previous report demonstrated that the extreme N termi-
nus of LANA1 is the chromosome-binding domain (38).
Therefore, we focused on this region and performed a DNA
replication assay with hybrid proteins containing various N-
terminal domains fused to the C terminus of LANA1. These
included amino acids 1 to 90 of KSHV LANA1 and EBNA-1,
corresponding to the chromosome-binding domain, the GAL4
DBD, and the VP16 AD (Fig. 5C). As shown in Fig. 5D, the
N-terminal 90 amino acids of LANA1 fused to the C terminus
efficiently facilitated KSHV TR replication. Interestingly,
KSHV TRs were also replicated in the presence of the EBNA-
1–LANA1 C hybrid, albeit relatively weakly. Western blotting
FIG. 2. Transcriptional activity of KSHV TRs is down-regulated by the C terminus of LANA1. (A) Schematic diagram of plasmids containing
KSHV TR variants used in transient reporter and replication assays. LBSs within TRs are indicated by black triangles. (B) 293T cells in a 60-mm
dish were cotransfected with 1 g of the indicated reporter and 4 g of pcDNA3 or pcDNA3 LANA1. Activation was calculated with respect to
the normalized luciferase activity of pGL2-basic in the presence of pcDNA3, which was set as 1. (C) 293T cells were cotransfected with 0.1 g of
the indicated reporter and 4 g of pcDNA3 or pcDNA3 LANA1. Activation was calculated with respect to the normalized luciferase activity of
pGL3-promoter in the presence of pcDNA3, which was set as 1. (D) 293T cells were cotransfected with 1 g of p4TR-luc and 4 g of the indicated
pcDNA3 derivatives. Activation was calculated with respect to the normalized luciferase activity of p4TR-luc in the presence of pcDNA3, which
was set as 100%. (E) 293T cells were cotransfected with 1 g of p4TR-luc and 4 g of the indicated VP16 derivatives. Activation was calculated
with respect to the normalized luciferase activity of p4TR-luc in the presence of VP16, which was set as 1. The results represent the averages of
at least three independent experiments, and standard deviations are depicted as error bars.
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with an anti-FLAG antibody revealed similar expression levels
for LANA1 	91–949 and EBNA-1–LANA1 C in transfected
293T cells (data not shown). This specificity of the N-terminal
domains of hybrid proteins was further confirmed by experi-
ments with GAL DBD-LANA1 C and VP16 AD-LANA1 C,
which failed to support the efficient replication of KSHV TRs.
KSHV LANA1 interacts with components of the ORCs.
EBNA-1 recruits cellular origin recognition complexes
(ORCs) to EBV oriP for latent replication of the genome (11,
14, 48). In theory, KSHV should also utilize cellular replication
machinery for the maintenance of the viral genome, since viral
proteins expressed during latent infection do not display enzy-
matic activity for DNA replication. LANA1, as an analog of
EBNA-1 that functions in the latent DNA replication of
KSHV, is a good candidate as an adaptor molecule linking the
viral origin of replication and cellular replication machinery.
Therefore, we used an in vitro binding assay to examine the
interactions between ORCs and KSHV LANA1. As shown in
Fig. 6A, in vitro-translated LANA1 was efficiently precipitated
in the presence of bacterially expressed GST-ORC1 and GST-
ORC2. GST-ORC4 and GST-ORC5 (but not GST alone) also
precipitated in vitro-translated LANA1 very weakly. The ad-
dition of 200 g of ethidium bromide/ml in binding buffer 2 did
not affect the binding affinity of LANA1 for GST-ORC1 and
GST-ORC2, confirming that these interactions are not medi-
ated by nonspecific DNA contaminants (data not shown).
Reciprocal pull-down experiments with His-tagged
LANA1 purified with a baculovirus expression system and in
vitro-translated ORC1 and ORC2 disclosed similar results
(Fig. 6B). Interestingly, the presence of ATP but not oligo-
nucleotides containing LBSs enhanced the binding affinity
between ORC1 or ORC2 and LANA1 (Fig. 6C). This ob-
FIG. 2—Continued.
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served augmentation of binding affinity by ATP disappeared
when lysates used in the in vitro translation assay were
frozen before inclusion in the binding reaction (data not
shown). The LANA1-binding regions of ORC1 and ORC2,
determined by similar GST pull-down assays with deletion
mutants of these complexes, were mapped to the relatively
nonconserved N-terminal regions, although very weak inter-
actions between the C terminus of ORC1 and in vitro-
translated LANA1 were additionally observed (Fig. 6D). On
the other hand, the ORC-binding region of LANA1, deter-
mined by including in vitro-translated proteins of various
LANA1 deletion mutants in a similar binding assay, was
mapped to a small region of the C terminus of LANA1 (Fig.
6E).
DISCUSSION
The viral genome of EBV is maintained as an episome by
cis- and trans-acting elements during latent infection. This ac-
tivity involves the semiconservative replication of the genome
once per cell cycle and equal segregation and partition of the
viral genome to daughter cells following mitosis of the host cell
(1, 53). The two distinct events are mediated, respectively, by
two components of EBV oriP, i.e., dyad symmetry and family
of repeats, which are separated by 1 kbp within the viral
genome (34, 42). The dyad symmetry and family-of-repeats
components contain multiple EBNA-1-binding sites with low
and high affinities, respectively (3, 41). EBNA-1 is the only
viral trans-acting element required for stable maintenance of
FIG. 3. Transient DNA replication of p4TR-luc in the presence of LANA1. (A) 293T cells in a 100-mm dish were cotransfected with 2 g of
p4TR-luc, 2 g of pGL2-basic, and 8 g of pcDNA3 or pcDNA3 LANA1. At 36 h posttransfection, cells were split and harvested at the indicated
times. LANA1 expression levels and cell numbers were monitored by Western blotting of total cell lysates with rabbit anti-LANA1 polyclonal
antiserum (upper panel) and anti--actin monoclonal antibody (lower panel), respectively. (B) Hirt-extracted DNA from transfected 293T cells was
digested with Alw44I/DpnI (right), and 10% of the samples were digested with Alw44I alone as input (left). Digested DNA was separated by 0.8%
agarose gel electrophoresis and analyzed by Southern blot hybridization with a probe specific for the luciferase gene. DNA size markers are
depicted on the left. (C) About 107 BJAB cells were cotransfected with 7.5 g of p4TR-luc, 7.5 g of pGL2-basic, and 15 g of pcDNA3 or
pcDNA3 LANA1. After electroporation, cells were split and harvested at the indicated times. Hirt-extracted DNA was digested with Alw44I alone
(left) or Alw44I/DpnI (right) and analyzed by Southern blotting. (D) 293T cells in a 100-mm dish were cotransfected with 2 g of p4TR-luc or
pFR-luc and 8 g of cytomegalovirus G4 or pcDNA3 derivatives. At 36 h posttransfection, cells were split and harvested at the indicated times.
Hirt-extracted DNA from transfected 293T cells was digested with Alw44I/DpnI (right). DNA extracted from cells harvested at 96 h posttrans-
fection was digested with Alw44I as input (left). Southern blotting was performed with a luciferase gene-specific probe.
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the viral genome (32, 42), although it was previously reported
that oriP-containing plasmids undergo at least two rounds of
DNA replication in the absence of this element (2). Another
member of the gammaherpesviruses family, KSHV, displays
similar characteristics of latent replication. KSHV oriP corre-
sponds to an 800-bp TR sequence of the viral genome con-
taining an LBS. Moreover, LANA1 is the only viral trans-acting
element required for the maintenance of TR-containing plas-
mids, as verified by the long-term selection of drug resistance
in cells harboring oriP-containing plasmids (5, 6). Using a
transient DNA replication assay with a methylation-sensitive
enzyme, we additionally show here that KSHV TRs and
LANA1 function as viral cis- and trans-acting elements of
KSHV latent replication, respectively.
Interestingly, KSHV LANA1 and EBV EBNA-1 (functional
analogs of the viral latent replication factor) have similar do-
main structures, despite differences in their primary amino acid
sequences. Both proteins contain an N-terminal chromosome-
binding domain, an internal repeat sequence, and a C-terminal
DNA-binding and dimerization domain. The DNA-binding
and dimerization domain of EBNA-1 alone is not sufficient for
the efficient replication of EBV oriP, and the additional chro-
mosome-binding domain/DNA-linking region is required (22,
25, 33); the latter may be substituted for by the chromosome-
binding domain of the high-mobility group 1 protein or histone
H1 (22). For KSHV LANA1, similar results were obtained
with various LANA1 deletion mutants and hybrid proteins,
although the chromosome-binding domain of EBNA-1 could
not fully replace that of LANA1 in domain-swapping experi-
ments. It is possible that the viral genomes of KSHV and EBV
FIG. 4. Transient replication of KSHV TR variants in the presence of LANA1. The indicated plasmids (2 g) containing variable numbers of
KSHV TR units (A) or reverse-oriented TR units (B) were cotransfected with 2 g of pGL2-basic and 8 g of pcDNA3 LANA1 into 293T cells.
After cells were harvested at the indicated times, Hirt-extracted DNA was digested and analyzed by Southern blotting with a luciferase
gene-specific probe as described in the legend to Fig. 3.
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attach to distinct sites of host chromosomes (via the respective
chromosome-binding domains of LANA1 and EBNA-1) where
latent replication of the viral genome occurs or that structural
differences between these regions result in different efficiencies
of replication. Other possibilities, including unknown functions
of the N terminus of LANA1 that may contribute to efficient
replication mediated by the C terminus of LANA1, cannot be
excluded.
LANA1 and EBNA-1 do not display enzymatic activities,
such as helicase or ATPase, required for replication events,
unlike SV40 large T antigen, bovine papillomavirus 1 E1, and
origin-binding protein of herpes simplex virus type 1, which are
involved in viral replication (7, 50, 52). Since viral oriP is
replicated by cellular machinery and LANA1 and EBNA-1 are
the only trans-acting elements supporting the latent replication
of the cis-acting element, it is reasonable to assume that these
proteins target cellular replication machinery to the viral origin
of replication and synchronize viral replication with that of
host cells. Recent data suggest that ORCs are recruited to
EBV oriP by EBNA-1 (11, 14, 48). We additionally reveal that
LANA1 directly interacts with ORC components. The
LANA1-binding domains of ORC1 and ORC2 were identified
in the relatively nonconserved N termini (19), a result which
may explain the host range that is permissive to viral genome
replication. It is noteworthy that the ORC-binding region of
LANA1 was mapped to the C terminus of the protein in a GST
FIG. 5. Determination of LANA1 domains required for p4TR-luc replication in a transient replication assay. Plasmids p4TR-luc and pGL2-
basic (2 g) were cotransfected with 8 g of pcDNA3 LANA1 derivatives, including the N-terminal or C-terminal deletion mutants of LANA1
(A), or pFLAG-CMV2 LANA1 derivatives, including the N-terminal or internal deletion mutants of LANA1 (B), into 293T cells. Cells were
harvested at 72 h posttransfection, and Hirt-extracted DNA was digested with Alw44I/DpnI. Southern blotting with a luciferase gene-specific probe
was performed as described above. (C) Schematic diagram of LANA1 hybrid proteins used in a transient replication assay with p4TR-luc.
(D) Plasmids (8 g) expressing the indicated hybrid proteins were cotransfected with 2 g of p4TR-luc and 2 g of pGL2-basic into 293T cells.
Hirt-extracted DNA from cells harvested at 72 h posttransfection was digested with Alw44I/DpnI and probed with a luciferase gene-specific probe.
F, FLAG-tagged.
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pull-down assay (Fig. 6E). Therefore, the inability of the N-
terminal deletion mutants of LANA1 to support KSHV TR
replication is not due to the loss of an interaction with ORCs.
KSHV displays distinct latent replication characteristics. Se-
quence analyses have revealed that a GC-rich sequence within
KSHV TRs contains various zinc finger transcription factor-
binding sites. Additionally, the p4TR-luc reporter is responsive
to several cellular factors (data not shown), and individual TR
units act as enhancer elements (17), like other viral origins of
replication, such as those of EBV, SV40, polyomavirus, and
bovine papillomavirus. However, the binding of LANA1 in-
duced the repression of the transcriptional activation of KSHV
TRs (17), in contrast to that of EBNA-1 to the EBV origin of
replication, which resulted in transcriptional activation (42,
43). The results of the transient replication assays with various
TR constructs showed that the number of TR units, but not the
orientation or basal transcriptional activity of TRs, significantly
affects the efficiency of replication, implying that the replica-
tion and transcription of KSHV TRs may be somehow uncou-
pled.
Recently, Garber et al. (18) reported that LANA1 coop-
eratively binds to two adjacent sites separated by 21 bp
within a single unit of KSHV TRs. They demonstrated that
LANA1 binds first to LBS 1, corresponding to TR-13, with
a high affinity, and then has an increased affinity for LBS 2;
they concluded that the binding affinity of LANA1 for the
LBS correlates with the transcriptional suppression and rep-
lication of KSHV TRs. Since p0TR-luc contains both LBS 1
and LBS 2, its low efficiency of transcriptional repression
and replication by LANA1 may be due not to the loss of
high-affinity binding sites but to insufficient numbers of LBS
1 and LBS 2. Since Garber et al. (18) manipulated a single
unit of TRs and used them in transient reporter and repli-
cation assays, they could not show the different efficiencies
of transcriptional suppression and replication on the basis of
the number of TRs. Further studies are required to deter-
mine the relationship between replication and transcription
of the KSHV TR region. The mechanism by which LANA1
represses KSHV TRs and its biological significance are cur-
rently under investigation.
incubated with His-tagged LANA1 or the LANA1 N purified from
insect cells infected with the appropriate recombinant baculovirus.
After precipitation with Ni2-nitrilotriacetic acid–agarose, bound pro-
teins were subjected to autoradiography. (C) ATP (1 mM) and a
double-stranded oligonucleotide (50 pmol) containing the LANA1-
binding sequence (TR-13) were included in a GST pull-down assay.
(D) ORC1 (left panel) or ORC2 (right panel) deletion mutants fused
to GST were used in a binding assay. Bound proteins were subjected to
autoradiography (upper panels); Coomassie blue staining of GST fu-
sion proteins used in a pull-down assay is also shown (lower panels).
Protein markers are shown to the left of Coomassie blue stain panels.
GST proteins with the correct size are indicated by asterisks. (E) (Left
panel) Schematic diagram of LANA1 deletion mutants used in GST
pull-down assays. DED, aspartate/glutamate-rich repeat region. (Right
panel) Each LANA1 deletion mutant was in vitro translated in the
presence of 35S-methionine and then used in GST pull-down assays.
The results obtained with GST, GST-ORC1, and GST-ORC2 are
shown. Input, 10% in vitro-translated proteins used in the binding
assay.
FIG. 6. Interactions between KSHV LANA1 and ORCs. (A) In
vitro-translated LANA1 in the presence of 35S-methionine was incu-
bated with glutathione-Sepharose 4B precoated with the indicated
GST fusion proteins. Bound proteins were subjected to autoradiogra-
phy (upper panel); Coomassie blue staining of GST fusion proteins
used in a pull-down assay is also depicted (lower panel). (B) In vitro-
translated ORC1 or ORC2 in the presence of 35S-methionine was
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